New state laws aim to clarify abortion bans. Doctors say it's not so simple.
Texas, Kentucky and Tennessee all passed laws this year ostensibly clarifying the scope of its abortion bans, a reaction to climbing sepsis rates and harrowing stories of patients who have suffered or died preventable deaths. Since June 2022, lawmakers in at least nine states have introduced such bills.
But doctors, attorneys and policy experts say that the laws being enacted will not solve the problems health providers have been forced to navigate since the end of Roe: The risk of being punished has deterred physicians, hospitals and health systems from providing consistent care, even when it is needed.
'The problem with these clarifying laws is they don't expand access under the law, they don't change the definitions, and they don't remove the legislative interference in the practice of medicine,' said Molly Meegan, chief legal officer and general counsel to the American College of Obstetricians and Gynecologists.
In Texas, a bill that awaits Republican Gov. Greg Abbott's signature ostensibly clarifies when the state's near-total abortion ban allows for the procedure, saying explicitly that physicians do not need to wait until a patient is in imminent danger of dying to perform an abortion. The bill also requires training for doctors and lawyers on the state's abortion law.
But lawmakers have made clear that the bill, crafted in consultation with Texas-based health professionals and abortion opponents, does not introduce new exceptions; Texas' ban does not allow for abortions in cases of rape, incest or fatal fetal anomaly. And if enacted, it would codify a Texas Supreme Court decision that found that the state's ban still applied even in cases with complications that could threaten a pregnant person's health.. Such was the case for Dallas woman Kate Cox, who experienced amniotic fluid leaking and cramping — which create the risk of bacterial infection — after discovering a likely-fatal fetal anomaly in her pregnancy.
Some former abortion patients whose lives were endangered because of delayed or denied care, including several who challenged the Texas abortion ban, said they fear Senate Bill 31 may not address situations like theirs.
Amanda Zurawski, who sued the state after being denied an abortion when experiencing a life-threatening condition called preterm premature rupture of membrane, said at a legislative hearing on the bill that it likely doesn't provide the clarity she would have needed.
'It is unclear whether SB 31 would have prevented my trauma and preserved my fertility had it existed in 2022, and I find that problematic,' Zurawski said. She only received care after she developed sepsis.
Clarification bills can have mixed support in legislatures. Local physicians might back tweaks to exemption language if they see it as potentially lifesaving for their patients. Some anti-abortion advocates might also favor changes if the legislation can address certain medical emergencies that they believe fall outside of a state's ban, such as ectopic pregnancies or preterm premature rupture of membranes.
But not all anti-abortion advocates or Republican lawmakers within these statehouses support even a small clarification.
'I think in all these cases, lawmakers are being pulled in different directions by these different constituencies,' said Mary Ziegler, an abortion law historian at the University of California, Davis. 'The bills themselves are kind of muddy, because they're trying to be different things to different people.'
The end result are clarification laws that remain unclear to physicians and their employing hospitals and health systems, who can still face high penalties for violating an abortion ban.
'When the law isn't clear, physicians don't intervene,' Ziegler said. 'You're not going to be willing to gamble your liberty and your medical license on an uncertain interpretation of the law.'
In Kentucky, doctors vocally opposed a Republican-backed bill that supporters said would help health professionals understand when they can provide abortions. Like in Texas, the state's ban only allows abortion when it is necessary to save a pregnant person's life. The clarification bill listed specific conditions that would qualify for an exception to the ban — such as sepsis, hemorrhage or ectopic pregnancy — despite concern from doctors that a delineated list wouldn't be able to predict every possible situation where an abortion might save someone's life.
Democratic Gov. Andy Beshear vetoed the bill in March, calling gaps in the law 'literally a matter of life and death.' The state's legislature, where the GOP holds a supermajority, voted days later to override him.
'It's hard to create this laundry list of, 'This is OK, this is not OK,' because unfortunately, medicine is something with a bunch of gray areas,' said Dr. Caitlin Thomas, an OB-GYN in Louisville.
In Georgia — where pregnant, brain-dead woman Adriana Smith remains on life-support until she can give birth later this summer, and where the death of Amber Thurman was attributed to the confusion created by the state's abortion ban — some lawmakers have asked physicians whether a clarification might allow doctors to provide abortions when the pregnancy threatens a patient's life, possibly by listing specific conditions that qualify for an exception.
'We encouraged them not to, and said that would not be helpful,' said Dr. Neesha Verma, an Atlanta-based OB-GYN. 'The more and more prescriptive you make these laws, the less space there is for clinical judgment.'
Following a case filed by seven Tennessee patients who had been denied abortions under the state's ban, lawmakers in that state passed a law this year meant to clarify that, under the state's ban, abortions could be performed in cases of preterm prelabor rupture of membrane or severe preeclampsia, but that the exception did not include mental health emergencies. Mental health conditions including substance use disorder, depression and confirmed or probably suicide are the largest single cause of pregnancy-related deaths in the state, according to a 2022 report.
The interest in clarifying bans — including from some lawmakers who oppose abortion — 'is a response to where we know the public is and the fact that we know the public is generally supportive of abortion access and also has been presented with these terrible preventable cases since Dobbs,' said Kimya Forouzan, who tracks state policy for the Guttmacher Institute, a nonprofit abortion research organization.
That ambiguity was on display in a Texas case last year. A state judge held that the state's abortion law exception permitted Cox to have an abortion when her doctors discovered the anomaly in her pregnancy. But the state's attorney general, Ken Paxton, swiftly intervened, threatening legal action against any health care provider that performed an abortion on Cox. Cox ultimately left the state to terminate her pregnancy.
Michele Goodwin, a law professor at the University of California, Irvine and author of 'Policing the Womb: Invisible Women and the Criminalization of Motherhood,' said state officials can do more to ensure health providers know their legal rights.
'It would be credible for states' attorneys generals and the prosecutors who are conservative to immediately issue statements of clarity, saying that they are opposed to these kinds of conditions, that they will not prosecute,' she said.
The post New state laws aim to clarify abortion bans. Doctors say it's not so simple. appeared first on The 19th.
News that represents you, in your inbox every weekday. Subscribe to our free, daily newsletter.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 'RENEW' clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median survival after diagnosis is just 3–5 years. Rein's LTI-03 is a first-in-class therapy that is designed to directly target fibrosis while also protecting the lung's ability to regenerate healthy tissue. If successful, it could represent a major breakthrough in how pulmonary fibrosis is treated. Brian Windsor, Chief Executive Officer of Rein Therapeutics, commented, 'This MHRA approval marks an important milestone not only for Rein, but also for patients living with IPF. We are now working towards patient recruitment in the U.K., advancing LTI-03 into the next stage of development. Our approach is designed not only to slow disease progression, but also to preserve, and potentially restore, the lung cells that are critical to everyday breathing and quality of life. We believe LTI-03 has the potential to transform outcomes for patients while also creating substantial value for our shareholders.' Next Steps The RENEW trial is expected to enroll up to 120 patients worldwide, evaluating two dose groups of LTI-03 against a placebo. The primary objective of the trial is to assess safety and tolerability over 24 weeks of treatment. Secondary endpoints will include measures of lung function and imaging-based assessments of fibrosis progression. Rein is actively working with clinical sites in the UK to begin patient recruitment soon, with initial data expected in 2026. About Rein Therapeutics Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. Forward-Looking Statements This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to expectations for the Company's LTI-03 product candidate, the planned UK Phase 2 clinical trial of LTI-03 and the initial data readouts from the planned UK clinical trial. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including (i) the risk that the Company may not be able to successfully undertake the planned UK Phase 2 clinical trial of LTI-03, (ii) success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (iii) the risk that the Company may not be able to obtain additional working capital with which to initiate and complete planned UK clinical trial, (iv) the risk that the Company may not be able to announce initial data readouts from the planned UK clinical trial in 2026 or, if it is able to do so, that the data may not be favorable and (v) those other risks disclosed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Rein Investor Relations & Media Contact: Investor Relations IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Forbes
an hour ago
- Forbes
Psilocybin Added To Substance Abuse Treatment Toolbox In New Mexico
Psilocybin is being increasingly used as an adjunctive therapy to treat substance abuse disorders, such as alcoholism or opioid abuse. It's been decriminalized or legalized in a handful of states and cities, with New Mexico recently joining this list, creating a legal pathway for the medical use of psilocybin. Governor Michelle Lujan Grisham signed Senate Bill 219 on April 7, legalizing psilocybin for a handful of qualifying conditions—major treatment-resistant depression, post-traumatic stress disorder (PTSD), end-of-life care, and substance use disorder— under the supervision of a medical provider. The Medical Psilocybin Act took effect on June 20, but it will take a few years for psilocybin production and a fully functional program to take shape in the state. Following the law's passage, Roswell-based Renew Health announced it will integrate psilocybin into its services, calling the move 'a major step forward in modern mental health and addiction care.' 'We have a real opportunity to become a national leader,' Renew Health founder Trent Carter says in a phone call. 'I've been introduced to mental health care. I hope that we can take advantage of that. And I hope that we do keep this safe and that we focus on patient safety, clinical integrity, and accessibility.' Renew Health, an outpatient clinic network, specializes in substance abuse and co-occurring mental health conditions. The clinic combines medication-assisted treatment such as Suboxone and naltrexone with counseling, cognitive behavioral therapy, family therapy, and harm reduction. It also provides detox services, withdrawal management, and telehealth care across New Mexico. Psilocybin And Its Role in Treating Addiction Carter is author of The Recovery Tool Belt, a comprehensive guide to addiction treatment, backed by principles and practical tools. The book focuses on the core conventional approaches to substance abuse disorders. Psilocybin represents a new facet of mental health care, providing a new type of tool that can be used for the complexity of addiction. He supports expanding medication-assisted treatment (MAT) and trauma-informed approaches. 'The goal isn't to replace what we already have—that's already been proven,' Carter says, speaking of conventional approaches to substance abuse therapy. 'It's to add another powerful tool to the toolbox, so to speak. But that's what I often tell my patients. They're tools to be used for you for this journey of addiction care and treatment. And so if we can use psilocybin as an adjunct therapy for patients who are stuck in these same cycles of trauma and addiction, that really has a chance to have a greater impact." The company structures therapy and medical treatment to help those patients progress and integrate more effectively. To become a patient at Renew Health, you don't have to struggle with substance abuse, as they serve various other mental health disorders. Psilocybin will soon enter the picture and provide a new approach to rethinking treatment for substance abuse disorder. 'It's going to hopefully help change a lot of lives to where we can have this new adjunct therapy," Carter says, explaining that the introspection from psilocybin experiences could lead them to make wiser decisions. "And then again, I think that we should also couple that with the proven methods, those treatment that we already have. I think they should all work in tandem.' Psilocybin's new role in Mexico extends to aid in therapy for treatment-resistant depression, PTSD, end-of-life care, and substance use disorder. Renew Health is among the first to embrace this new change.


Axios
an hour ago
- Axios
Eight Sleep raises $100 million, preps retail stores
Eight Sleep, a New York-based developer of smart sleep products, has raised $100m in Series D funding. Why it matters: This comes just weeks after RFK Jr. said that the Department of Health and Human Services will launch a giant advertising campaign aimed at encouraging the use of wearables. "My vision is that every American is wearing a wearable within four years," he told Congress. Eight Sleep's smart mattress cover isn't technically a wearable — users lie on top of it — but still fits within the category. Investors include HSG (fka: HongShan Capital/Sequoia Capital China) and insiders Valor Equity Partners, Founders Fund, and Y Combinator. Existing backer Khosla Ventures didn't participate.